Patents by Inventor Andrew J. Sedgewick

Andrew J. Sedgewick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MDS TO AML TRANSITION AND PREDICTION METHODS THEREFOR
    Publication number: 20190304570
    Abstract: Contemplated systems and methods allow for prediction of time for MDS to AML transition using a predictive model that is based on selected features with significant differential expression levels and/or pathway activity between MDS to AML cells.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 3, 2019
    Inventors: Stephen Charles Benz, Andrew Nguyen, Andrew J. Sedgewick, Christopher Szeto
  • PARP genomic variants conferring resistance and sensitization to chemotherapy under inhibition
    Patent number: 10260108
    Abstract: A method is provided for selecting a subject diagnosed with cancer as a candidate for treatment with a PARP1 inhibitor, or both a PARP1 inhibitor and a chemotherapeutic agent such as an alkylating agent. The method includes detecting the presence or absence of a mutation in a non-coding region of a PARP1 gene, wherein the presence of a mutation in the PARP1 gene indicates that the cancer can be treated with the PARP1 inhibitor, optionally in conjunction with the chemotherapeutic agent. In a specific, non-limiting example, the PARP1 inhibitor is verliparib (ABT-888).
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: April 16, 2019
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Hussein A. Tawbi, Petr Pancoska, Panagiotis Benos, Marjorie Romkes, Andrew J. Sedgewick, Irina Abecassis
  • PARP GENOMIC VARIANTS CONFERRING RESISTANCE AND SENSITIZATION TO CHEMOTHERAPY UNDER INHIBITION
    Publication number: 20170342498
    Abstract: A method is provided for selecting a subject diagnosed with cancer as a candidate for treatment with a PARP1 inhibitor, or both a PARP1 inhibitor and a chemotherapeutic agent such as an alkylating agent. The method includes detecting the presence or absence of a mutation in a non-coding region of a PARP1 gene, wherein the presence of a mutation in the PARP1 gene indicates that the cancer can be treated with the PARP1 inhibitor, optionally in conjunction with the chemotherapeutic agent. In a specific, non-limiting example, the PARP1 inhibitor is verliparib (ABT-888).
    Type: Application
    Filed: October 30, 2015
    Publication date: November 30, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Hussein A. Tawbi, Petr Pancoska, Panagiotis Benos, Marjorie Romkes, Andrew J. Sedgewick, Irina Abecassis
  • Systems And Methods For Learning And Identification Of Regulatory Interactions In Biological Pathways
    Publication number: 20150262082
    Abstract: Contemplated systems and methods provide for machine learning and identification of regulatory interactions in biological pathways using a probabilistic graphical model, and especially for identification of interaction correlations among the regulatory parameters.
    Type: Application
    Filed: October 9, 2013
    Publication date: September 17, 2015
    Inventors: Charles Joseph Vaske, Andrew J. Sedgewick, Stephen Charles Benz